Market Overview:
The global macular edema therapeutics market is expected to grow at a CAGR of 7.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of age-related macular degeneration (AMD) and diabetic retinopathy (DR), rising awareness about available treatment options, and technological advancements in the field of ophthalmology. Based on type, the global macular edema therapeutics market can be segmented into laser treatment, anti-VEGF injection, anti-inflammatory treatment, and vitrectomy. The laser treatment segment is expected to account for the largest share of the global market in 2018 owing to its high efficacy and growing demand for minimally invasive procedures. By application, cystoid macular edema (CME) is expected to account for the largest share of the global market in 2018 followed by diabetic macular edema (DME).
Product Definition:
Macular edema (ME) is a common complication of diabetes and can cause severe vision loss. The aim of ME therapy is to reduce the risk of vision loss by reducing the amount of fluid that accumulates in the macula, the part of the eye responsible for central vision. Therapeutic strategies include laser treatment, medications, and surgery.
Laser Treatment:
Macular edema is caused by a build-up of fluid in the macula, which is located in the center of the retina. The macula swells and becomes red and painful. This condition affects one eye more than other; therefore, it's referred to as bilateral macular edema (BME). BME can be treated with laser treatment that reduces swelling and pain by destroying abnormal tissue responsible for causing inflammation around the nerve fiber layer of retina.
Anti-VEGF Injection:
Anti-Vascular Endothelial Growth Factor (VEGF) Injection is used for the treatment of macular edema. Macular edema is a buildup of fluid in the center of the retina due to an increase in blood flow to that area. The most common symptom associated with macular edema is blurring or vision loss from central vision due to swelling or redness in the eye.
Application Insights:
CME accounted for the largest share of the global macular edema therapeutics market in 2017. CME is observed to be more prevalent among older people and those having a family history of eye diseases. It has been reported that approximately 80% of patients suffering from CME are 60 years or above, while 50% are above 60 years old. In addition, it has also been reported that patients with diabetes mellitus have a higher risk of developing CME as compared to non-diabetic individuals.
On basis on application type DMTs can be classified into diabetic macular edema and cystoid macular edema segments which in turn will contribute towards revenue growth during the study period.
Regional Analysis:
North America dominated the global market in 2017. The region is expected to maintain its position during the forecast period due to increasing cases of macular edema, rise in diabetic retinopathy and proliferative diabetic retinopathy, increase in per capita healthcare expenditure and presence of well-established healthcare facilities. Moreover, high adoption of advanced treatment procedures such as laser photocoagulation is also one of the major factors responsible for regional growth.
Asia Pacific is anticipated to be the fastest growing region over the forecast period owing to a large population base suffering from macular edema disorders coupled with rising disposable income levels especially in developing countries such as China & India are expected boost this regional segment growth significantly over next eight years. In addition, increasing awareness about various treatment options available for these diseases will further propel market development during this period.
Growth Factors:
- Increasing prevalence of macular edema
- Growing awareness about the available treatment options for macular edema
- Rising demand for better and more effective therapies for macular edema
- Technological advancements in the field of ophthalmology that are helping to improve diagnosis and treatment of macular edema 5. increasing investment in research and development activities aimed at developing new and better therapies for macULAR EDEMA
Scope Of The Report
Report Attributes
Report Details
Report Title
Macular Edema Therapeutics Market Research Report
By Type
Laser Treatment, Anti-VEGF Injection, Anti-Inflammatory Treatment, Vitrectomy
By Application
Cystoid Macular Edema (CME), Diabetic Macular Edema(DME)
By Companies
Allergan, Novartis, Roche, Regeneron Pharmaceuticals, Pfizer, Bayer, Boehringer Ingelheim, Bausch & Lomb, Aciont, ActiveSite Pharmaceuticals, Adverum Biotechnologies, Aerpio Therapeutics, Ampio Pharmaceuticals, Araim Pharmaceuticals, Astellas Pharma
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
167
Number of Tables & Figures
117
Customization Available
Yes, the report can be customized as per your need.
Global Macular Edema Therapeutics Market Report Segments:
The global Macular Edema Therapeutics market is segmented on the basis of:
Types
Laser Treatment, Anti-VEGF Injection, Anti-Inflammatory Treatment, Vitrectomy
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Cystoid Macular Edema (CME), Diabetic Macular Edema(DME)
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Allergan
- Novartis
- Roche
- Regeneron Pharmaceuticals
- Pfizer
- Bayer
- Boehringer Ingelheim
- Bausch & Lomb
- Aciont
- ActiveSite Pharmaceuticals
- Adverum Biotechnologies
- Aerpio Therapeutics
- Ampio Pharmaceuticals
- Araim Pharmaceuticals
- Astellas Pharma
Highlights of The Macular Edema Therapeutics Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Laser Treatment
- Anti-VEGF Injection
- Anti-Inflammatory Treatment
- Vitrectomy
- By Application:
- Cystoid Macular Edema (CME)
- Diabetic Macular Edema(DME)
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Macular Edema Therapeutics Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Macular edema is a condition that results from an increase in fluid pressure inside the macula, the area at the center of your retina. This increased pressure can cause damage to the macula and lead to vision loss. Macular edema is most common in people over age 60, but it can also occur in younger adults. There are many different treatments for macular edema, but no cure.
Some of the major players in the macular edema therapeutics market are Allergan, Novartis, Roche, Regeneron Pharmaceuticals, Pfizer, Bayer, Boehringer Ingelheim, Bausch & Lomb, Aciont, ActiveSite Pharmaceuticals, Adverum Biotechnologies, Aerpio Therapeutics, Ampio Pharmaceuticals, Araim Pharmaceuticals, Astellas Pharma.
The macular edema therapeutics market is expected to register a CAGR of 7.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Macular Edema Therapeutics Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Macular Edema Therapeutics Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Macular Edema Therapeutics Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Macular Edema Therapeutics Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Macular Edema Therapeutics Market Size & Forecast, 2020-2028
4.5.1 Macular Edema Therapeutics Market Size and Y-o-Y Growth
4.5.2 Macular Edema Therapeutics Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Laser Treatment
5.2.2 Anti-VEGF Injection
5.2.3 Anti-Inflammatory Treatment
5.2.4 Vitrectomy
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Cystoid Macular Edema (CME)
6.2.2 Diabetic Macular Edema(DME)
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Macular Edema Therapeutics Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Macular Edema Therapeutics Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Laser Treatment
9.6.2 Anti-VEGF Injection
9.6.3 Anti-Inflammatory Treatment
9.6.4 Vitrectomy
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Cystoid Macular Edema (CME)
9.10.2 Diabetic Macular Edema(DME)
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Laser Treatment
10.6.2 Anti-VEGF Injection
10.6.3 Anti-Inflammatory Treatment
10.6.4 Vitrectomy
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Cystoid Macular Edema (CME)
10.10.2 Diabetic Macular Edema(DME)
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Laser Treatment
11.6.2 Anti-VEGF Injection
11.6.3 Anti-Inflammatory Treatment
11.6.4 Vitrectomy
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Cystoid Macular Edema (CME)
11.10.2 Diabetic Macular Edema(DME)
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Laser Treatment
12.6.2 Anti-VEGF Injection
12.6.3 Anti-Inflammatory Treatment
12.6.4 Vitrectomy
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Cystoid Macular Edema (CME)
12.10.2 Diabetic Macular Edema(DME)
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Laser Treatment
13.6.2 Anti-VEGF Injection
13.6.3 Anti-Inflammatory Treatment
13.6.4 Vitrectomy
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Cystoid Macular Edema (CME)
13.10.2 Diabetic Macular Edema(DME)
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Macular Edema Therapeutics Market: Competitive Dashboard
14.2 Global Macular Edema Therapeutics Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Allergan
14.3.2 Novartis
14.3.3 Roche
14.3.4 Regeneron Pharmaceuticals
14.3.5 Pfizer
14.3.6 Bayer
14.3.7 Boehringer Ingelheim
14.3.8 Bausch & Lomb
14.3.9 Aciont
14.3.10 ActiveSite Pharmaceuticals
14.3.11 Adverum Biotechnologies
14.3.12 Aerpio Therapeutics
14.3.13 Ampio Pharmaceuticals
14.3.14 Araim Pharmaceuticals
14.3.15 Astellas Pharma
